Replies to post #3898 on Halozyme Therapeutics Inc (HALO)

[friendofthedevil]

Thanks for sharing this. ASCO seems way too optimistic, though.

>>>As of March 3, the OS data was still maturing, putting the median follow-up of Study 202 patients at ~8.5 months currently. Since OS was 8.5 months in the pivotal Abraxane + gemcitabine trial, we expect Study 202 OS data could be presented at the American Society for Clinical Oncology meeting in May/June," the analysts wrote. <<<

HALO restarted 202 in August and were still enrolling subjects in 1Q'15. I estimate the trial just now is finally closing. So, we are now 8.5 mos out from only the first subject. Not sure how they can get too much by ASCO in June. Prelim PFS data might be relevant by then but I believe ASCO requires abstracts in February. Late breaking data can be later but should be Ph3 with expected maturity before April.

So, no ASCO, IMO, unless they want to present OS on that early 'pre-halt' cohort??

fotd